Investigation Report on China Thymosin α1 Market

Investigation Report on China Thymosin α1 Market

Bharat Book Bureau provides the report, on “Investigation Report on China Thymosin α1 Market ” The report Present The Overview of the Thymosin products which can enhance body immunity are mainly used in the treatment of hepatitis and tumor and can be categorized into thymosin (extracted), thymopentin and thymosin α1, a high-end product. https://www.bharatbook.com/drugs-market-research-reports-678099/investigation-china-thymosin.html

17th Dec 2015- Mumbai, India: Bharatbook.com announces a report on “Investigation Report on China Thymosin α1 Market” The report also Discussed Thymosin α1 develops fast after entering China, annual sales value rising from less than CNY 7 million in 2005 to CNY 968 million in 2014 and CAGR reaching up to 73.7%. currently, thymosin α1 in the Chinese market mainly come from Diao Group, Suzhou Tianma Pharma Group Tianji BIO-pharmaceutical Co., Ltd and Hainan Shuangcheng Pharmaceuticals Co., Ltd, among which Diao Group has the largest market share of about 36% for sales volume in 2014

Thymosin products which can enhance body immunity are mainly used in the treatment of hepatitis and tumor and can be categorized into thymosin (extracted), thymopentin and thymosin α1, a high-end product.

First developed by SciClone Pharmaceuticals, Inc., thymosin α1’s being used for tumor immunotherapy as immunomodulator has increasingly gained people’s attention. In the clinic, it has been used for the treatment of many kinds of tumors like non-small cell lung cancer, malignant melanoma, liver cancer, non-Hodgkin lymphomia and so on. Research has shown that thymosin α1 can enhance patients’ immunity, reduce side effects and infection rate, improve life quality and raise remission rate or even survival rate in the chemotherapy for tumors. As a vaccine adjuvant, thymosin α1 can boost the immune response to viral vaccines like influenza vaccine and hepatitis B vaccine in patients whose immune systems...